Abstract

Pseudomonas aeruginosa is a re-emerging, multidrug-resistant, opportunistic pathogen that threatens the lives of immunocompromised patients, patients with cystic fibrosis, and those in critical care units. One of the most important virulence factors in this pathogen is the siderophore pyoverdine. Pyoverdine serves several critical roles during infection. Due to its extremely high affinity for ferric iron, pyoverdine gives the pathogen a significant advantage over the host in their competition for iron. In addition, pyoverdine can regulate the production of multiple bacterial virulence factors and perturb host mitochondrial homeostasis. Inhibition of pyoverdine biosynthesis decreases P. aeruginosa pathogenicity in multiple host models. To better understand the regulation of pyoverdine production, we developed a high-throughput genetic screen that uses the innate fluorescence of pyoverdine to identify genes necessary for its biosynthesis. A substantial number of hits showing severe impairment of pyoverdine production were in genes responsible for early attachment and biofilm formation. In addition to genetic disruption of biofilm, both physical and chemical perturbations also attenuated pyoverdine production. This regulatory relationship between pyoverdine and biofilm is particularly significant in the context of P. aeruginosa multidrug resistance, where the formation of biofilm is a key mechanism preventing access to antimicrobials and the immune system. Furthermore, we demonstrate that the biofilm inhibitor 2-amino-5,6-dimethylbenzimidazole effectively attenuates pyoverdine production and rescues Caenorhabditis elegans from P. aeruginosa-mediated pathogenesis. Our findings suggest that targeting biofilm formation in P. aeruginosa infections may have multiple therapeutic benefits and that employing an unbiased, systems biology-based approach may be useful for understanding the regulation of specific virulence factors and identifying novel anti-virulence therapeutics or new applications for existing therapies for P. aeruginosa infections.

Highlights

  • Antibiotic resistance is a catastrophic, re-emerging threat to health care

  • We showed that disrupting biofilm formation either genetically or chemically was sufficient to rescue C. elegans from pyoverdinemediated pathogenesis

  • We demonstrated that cyclic-diguanylate monophosphate (c-di-GMP), a secondary messenger and master regulator of virulence factors in the pathogen, regulates pyoverdine production in a biofilm-dependent manner

Read more

Summary

Introduction

Multidrug-resistant nosocomial infections increase the danger to hospitalized patients and drastically increase healthcare costs (Brusselaers et al, 2011). Despite the fact that multi-drug resistant P. aeruginosa is already responsible for more than 13% of hospital-acquired P. aeruginosa infections, poor understanding of P. aeruginosa pathogenesis has limited viable treatments to conventional antimicrobials (Centers for Disease Control and Resistance, 2013). The pathogen readily acquires additional resistance mechanisms from other microbes. These phenomena make it imperative that we develop new treatments, beyond conventional antimicrobials

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.